A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Clinical trial NCT07490262 · RECRUITING
Trial details
- NCT number
- NCT07490262
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-27
- Primary completion
- 2027-12-31
- Enrollment
- 680
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.